Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis

References

• Aghajanian, C., et al. 2021. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: analysis of the VELIA/GOG-3005 trial. Gynecologic Oncology, 162 (2), 375–381.
   PubMed Web of Science ®Google Scholar
• Banerjee, S., et al. 2021. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 22, 1721–1731.
   PubMed Web of Science ®Google Scholar
• Barkauskaite, E., Jankevicius, G. and Ahel, I., 2015. Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation. Molecular Cell, 58 (6), 935–946.
   PubMed Web of Science ®Google Scholar
• Boussios, S., et al. 2022. BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers, 14 (16):3888.
   PubMed Web of Science ®Google Scholar
• Bray, F., et al. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68 (6), 394–424.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609–615.
   PubMed Web of Science ®Google Scholar
• Colombo, N., et al. 2019. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 30 (5), 672–705.
   PubMed Web of Science ®Google Scholar
• Dizon, D.S., 2017. PARP inhibitors for targeted treatment in ovarian cancer. The Lancet, 390, 1929–1930.
   PubMed Web of Science ®Google Scholar
• Domchek, S.M., et al. 2016. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology, 140 (2), 199–203.
   PubMed Web of Science ®Google Scholar
• Fabbro, M., et al. 2020. Conditional probability of survival and prognostic factors in long-term survivors of high-grade serous ovarian cancer. Cancers, 12 (8), 2184.
   PubMed Web of Science ®Google Scholar
• Ghose, A., et al. 2022a. Hereditary ovarian cancer: towards a cost-effective prevention strategy. International Journal of Environmental Research and Public Health, 19 (19), 12057.
   PubMed Web of Science ®Google Scholar
• Ghose, A., et al. 2022b. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes, 10 (2), 16.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin, A., et al. 2019. Niraparib in patients with newly diagnosed advanced ovarian cancer. The New England Journal of Medicine, 381 (25), 2391–2402.
   PubMed Web of Science ®Google Scholar
• Huang, X.Z., et al. 2020. Efficacy and prognostic factors for PARP inhibitors in patients with ovarian cancer. Frontiers in Oncology, 10, 958.
   PubMed Web of Science ®Google Scholar
• Kristeleit, R., et al. 2022. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. The Lancet. Oncology, 23 (4), 465–478.
   PubMed Web of Science ®Google Scholar
• Lafargue, C.J., et al. 2019. Exploring and comparing adverse events between PARP inhibitors. The Lancet. Oncology, 20 (1), e15–e28.
   PubMed Web of Science ®Google Scholar
• Ledermann, J.A., et al. 2016. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Oncology, 17 (11), 1579–1589.
   PubMed Web of Science ®Google Scholar
• Ledermann, J., et al. 2012. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England Journal of Medicine, 366 (15), 1382–1392.
   PubMed Web of Science ®Google Scholar
• Lin, Q., et al. 2021. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 128 (3), 485–493.
   PubMed Web of Science ®Google Scholar
• Matulonis, U.A., et al. 2016. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer, 122, 1844–1852.
   PubMed Web of Science ®Google Scholar
• Menon, U., et al. 2021. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet, 397, 2182–2193.
   PubMed Web of Science ®Google Scholar
• Mirza, M.R., et al. 2016. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. The New England Journal of Medicine, 375 (22), 2154–2164.
   PubMed Web of Science ®Google Scholar
• Monk, B.J., et al. 2022. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 40 (34), 3952–3964.
   PubMed Web of Science ®Google Scholar
• Moore, K., et al. 2018. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. The New England Journal of Medicine, 379 (26), 2495–2505.
   PubMed Web of Science ®Google Scholar
• Moschetta, M., et al. 2020. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Annals of Translational Medicine, 8 (24), 1710.
   PubMed Web of Science ®Google Scholar
• Mullen, M.M., Kuroki, L.M. and Thaker, P.H., 2019. Novel treatment options in platinum-sensitive recurrent ovarian cancer: a review. Gynecologic Oncology, 152 (2), 416–425.
   PubMed Web of Science ®Google Scholar
• Oaknin, A., et al. 2021. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: the effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Medicine, 10 (20), 7162–7173.
   PubMed Web of Science ®Google Scholar
• Pavlidis, N., et al. 2021. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiology, 75, 102045.
   PubMed Web of Science ®Google Scholar
• Pennington, K.P., et al. 2014. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research, 20 (3), 764–775.
   PubMed Web of Science ®Google Scholar
• Perego, G., et al. 2020. Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: are they really the same drug? Journal of Oncology Pharmacy Practice, 26 (4), 967–971.
   PubMed Web of Science ®Google Scholar
• Poveda, A., et al. 2021. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology, 22 (5), 620–631.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine, E., et al. 2017. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18 (9), 1274–1284.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard, I., et al. 2019. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. The New England Journal of Medicine, 381 (25), 2416–2428.
   PubMed Web of Science ®Google Scholar
• Salani, R., et al. 2011. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. American journal of Obstetrics and Gynecology, 204 (6), 466–478.
   PubMed Web of Science ®Google Scholar
• Siegel, R.L., Miller, K.D. and Jemal, A., 2015. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5–29.
   PubMed Web of Science ®Google Scholar
• Smith, M. and Pothuri, B., 2022. Appropriate selection of PARP inhibitors in ovarian cancer. Current Treatment Options in Oncology, 23 (6), 887–903.
   PubMed Web of Science ®Google Scholar
• Stone, A., et al. 2019. Exaggeration of PFS by blinded, independent, central review (BICR). Annals of Oncology, 30 (2), 332–338.
   PubMed Web of Science ®Google Scholar
• Swisher, E.M., et al. 2022. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology, 164 (2), 245–253.
   PubMed Web of Science ®Google Scholar
• Trillsch, F., et al. 2022. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecologic Oncology, 165 (1), 40–48.
   PubMed Web of Science ®Google Scholar
• Valabrega, G., et al. 2021. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. International Journal of Molecular Sciences., 22 (8), 4203.
   PubMed Web of Science ®Google Scholar
• Vergote, I., et al. 2022. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 33 (3), 276–287.
   PubMed Web of Science ®Google Scholar
• Wu, L., et al. 2021a. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecologic Oncology, 160 (1), 175–181.
   PubMed Web of Science ®Google Scholar
• Wu, X.H., et al. 2021b. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 32 (4), 512–521.
   PubMed Web of Science ®Google Scholar